Sugi Predict

Sugi Predict / Compounds / SCHEMBL2199558

SCHEMBL2199558

SCHEMBL2199558

C/C(=C\c1ccc(Br)cc1)[N+](=O)[O-]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 8/20 0.67
▸ LMNA P02545 3/20 0.64
▸ MAPT P10636 3/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ JAK2 O60674 1/20 0.64
▸ MITF O75030 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ NTSR1 P30989 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ EGFR P00533 2/20 0.59
▸ ABL1 P00519 1/20 0.59
▸ ABL2 P42684 1/20 0.59
▸ S1PR4 O95977 2/20 0.41
▸ S1PR1 P21453 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199559 1.00 FBP1 (0.67) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL27957137 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL27946453 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL2746679 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL2746675 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL10664676 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL2746676 0.82 FBP1 (0.69) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL6469695 0.81 FBP1 (0.67) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL1245803 0.81 FBP1 (0.67) FBP1LMNAMAPTMEN1KMT2A
SCHEMBL107299 0.81 FBP1 (0.67) FBP1LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982368-A1 Small molecule compounds displacing focal adhesion core components Universität Konstanz (DE) 2016-02-10 — — EP claimed
US-11912721-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2024-02-27 — — US disclosed
EP-3201196-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-28 — — EP disclosed
US-20210155637-A1 Fused Pentacyclic Imidazole Derivatives SANOFI (FR) 2021-05-27 — — US disclosed
US-10941114-B2 Small molecule lipid II inhibitors UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-03-09 — — US disclosed
US-10941114-B2 Small molecule lipid II inhibitors UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-03-09 — — US disclosed
US-10906919-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2021-02-02 — — US disclosed
US-20200399261-A1 INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF PHARMABLOCK SCIENCES (NANJING), INC. (CN) 2020-12-24 — — US disclosed
US-20200216394-A1 Small Molecule Lipid II Inhibitors UNIVERSITY OF MARYLAND, BALTIMORE 2020-07-09 — — US disclosed
US-20200216394-A1 Small Molecule Lipid II Inhibitors UNIVERSITY OF MARYLAND, BALTIMORE 2020-07-09 — — US disclosed
US-6596716-B2 2-propane-sulphonamide derivatives ELI LILLY AND COMPANY 2003-07-22 — — US disclosed
US-6525099-B1 Potentiating glutamate receptor function; psychiatric and neurological disorders ELI LILLY AND COMPANY 2003-02-25 — — US disclosed
US-6521605-B1 Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders ELI LILLY AND COMPANY 2003-02-18 — — US disclosed
US-20020002158-A1 Sulphonamide derivatives ARNOLD MACKLIN B (US) 2002-01-03 — — US disclosed
US-6303816-B1 Sulphonamide derivatives ELI LILLY AND COMPANY 2001-10-16 — — US disclosed
WO-2000006537-A1 N-SUBSTITUTED SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
WO-2000006176-A1 AMIDOPHOSPHATE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
WO-2000006156-A1 AMIDE, CARBAMATE, AND UREA DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 — — WO disclosed
EP-0976744-A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity ELI LILLY AND COMPANY (US) 2000-02-02 — — EP disclosed
EP-0860428-A2 Sulphonamide derivatives ELI LILLY AND COMPANY (US) 1998-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906919-B2 Fused pentacyclic imidazole derivatives TNF, NFKBIA, TNFRSF1A FBP1 734/4885LMNA 2126/4885MAPT 1366/4885
US-20020002158-A1 Sulphonamide derivatives GRIN2C, GRM1, GRM3 FBP1 1690/4885LMNA 2852/4885MAPT 4777/4885
US-20210155637-A1 Fused Pentacyclic Imidazole Derivatives TNF, NFKBIA, TNFRSF1A FBP1 734/4885LMNA 2126/4885MAPT 1366/4885
US-20200216394-A1 Small Molecule Lipid II Inhibitors DBI, FABP2, HDLBP FBP1 2712/4885LMNA 1606/4885MAPT 2236/4885
US-10941114-B2 Small molecule lipid II inhibitors DBI, FABP2, SREBF2 FBP1 3049/4885LMNA 1615/4885MAPT 2637/4885
US-11912721-B2 Fused pentacyclic imidazole derivatives TNF, NFKBIA, TNFRSF1A FBP1 734/4885LMNA 2126/4885MAPT 1366/4885
US-20200399261-A1 INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF PRMT5, PRMT1, PRMT3 FBP1 3981/4885LMNA 3766/4885MAPT 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback